Every 10-Q that XERIANT INC (XERI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XERI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XERI filings page.
Xeriant, Inc. reported net income of $1.93 million for the six months ended December 31, 2025, reversing a prior-year loss. This was driven almost entirely by a $2.74 million gain on extinguishment of debt from a settlement restructuring a senior secured note with Auctus Fund, while the core business recorded a $0.54 million operating loss.
The balance sheet remains very weak, with only $76,533 in cash, total assets of $103,440, and total liabilities of $5.74 million, resulting in a stockholders’ deficit of $5.64 million. Current liabilities include a $3.5 million settlement liability and $1.67 million of convertible notes payable, net of discount. The company also has a large potential overhang from warrants, options, preferred stock and convertible debt.
Management discloses that recurring losses, an accumulated deficit of $26.41 million, and a working capital deficit of $5.65 million raise substantial doubt about Xeriant’s ability to continue as a going concern. Based on its historical spending, the company expects its cash to last about two months from February 17, 2026, and plans to seek additional debt or equity financing while pursuing commercialization of its NEXBOARD™ advanced materials product.
Xeriant, Inc. reported quarterly results for the three months ended September 30, 2025, showing net income of $2,226,072 driven largely by a $2,743,546 gain on extinguishment of debt from a settlement of its senior secured note with Auctus Fund. Operating activities still produced a loss of $304,075 as the company continues to invest in consulting, R&D and professional fees while generating no disclosed revenue.
At September 30, 2025, Xeriant had cash of $52,136, total assets of $71,730 and a stockholders’ deficit of $5,702,498, including a working capital deficit of $5,710,579. Management states there is substantial doubt about the company’s ability to continue as a going concern and estimates existing cash would last about two months from mid-November 2025 without new funding. The company is pursuing additional capital via equity and debt while advancing its DUREVER and NEXBOARD advanced materials portfolio and maintaining an ongoing lawsuit against XTI Aircraft Company.